Memantin Ratiopharm (Memantine Hydrochloride)

Memantin Ratiopharm is used in the management of Alzheimer’s disease, a neurodegenerative condition affecting cognition and daily function.

• Alzheimer’s disease: improves cognition, global functioning and activities of daily living in mild to moderate stages.

• Memantine acts as a non‑competitive antagonist at the N‑methyl‑D‑aspartate (NMDA) receptor. By binding to the receptor-associated ion channel, it reduces excessive calcium influx caused by prolonged glutamate activation, thereby limiting excitotoxic neuronal injury that contributes to cognitive decline in Alzheimer’s disease.

Memantin Ratiopharm may cause a range of adverse reactions. Patients should be aware of both frequent and less common events.

Common Side Effects

• Dizziness: transient light‑headedness, especially after dose initiation.
• Headache: mild to moderate intensity, often resolves with continued therapy.
• Constipation: reduced bowel movements, manageable with diet or laxatives.
• Confusion: occasional disorientation, particularly in early treatment.
• Fatigue: feeling unusually tired or low energy.
• Hypertension: modest increase in blood pressure in some individuals.

Serious or Rare Side Effects

• Seizures: rare occurrence, requires immediate medical attention.
• Cardiac arrhythmia: abnormal heart rhythms reported infrequently.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hepatic injury: elevated liver enzymes or hepatitis.
• Suicidal ideation: emergent thoughts of self‑harm, necessitating urgent evaluation.
• Neuroleptic malignant syndrome: extremely rare but life‑threatening condition.

Before initiating Memantin Ratiopharm, clinicians should consider several safety aspects.

• Renal impairment: adjust dose or monitor closely in patients with reduced kidney function.
• Hepatic impairment: use with caution; liver function tests may be warranted.
• Concomitant NMDA antagonists: avoid combined use to reduce risk of additive neurotoxicity.
• Cardiovascular disease: monitor blood pressure and heart rhythm regularly.
• Pregnancy and lactation: safety not established; weigh potential benefits against risks.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Memantin Ratiopharm can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid)

• Amantadine: combined NMDA antagonism may increase neurotoxicity.
• Ketamine: additive CNS effects and heightened risk of seizures.
• Other NMDA receptor antagonists: may amplify adverse neurological events.

Moderate Interactions (Monitor Closely)

• Antihypertensive agents: memantine may attenuate blood‑pressure‑lowering effects.
• CNS depressants (e.g., benzodiazepines): increased sedation or dizziness.
• Diuretics: potential for electrolyte disturbances, especially potassium.
• Anticholinergic drugs: may worsen confusion or cognitive impairment.